FDA Finalizes Numerous Guidances, Issues New Master Protocol Guidance

As 2023 draws to a close, the FDA has issued several final guidances, including documents on collecting trial data with digital health technologies, developing rare disease drugs and biologics, and complying with a final rule on TV and radio prescription drug ads, as well as a new draft guidance on clinical trial master protocols.
Source: Drug Industry Daily